This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers.View CRIS key stats
Curis Inc - CRIS - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Curis Inc as a
Sell with a ratings score of D.
Report Snippet: We rate CURIS INC (CRIS) a SELL. This is driven by multiple weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.